[{"data":1,"prerenderedAt":235},["ShallowReactive",2],{"$f2qnisnuqqioiw":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":59,"top_diseases":85,"top_companies":115,"key_results":141,"trends":222,"previous_editions":231,"comparison":160,"highlighted_classes":232},1,"asco-gu-2026","ASCO GU","asco-gu","ASCO Genitourinary Cancers Symposium 2026",2026,"Oncology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},890,446,81,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":20,"Phase 3":21},28,38,112,2,67,[23,27,31,34,38,42,46,49,53,56],{"name":24,"count":25,"share":26},"PVRL4",59,13,{"name":28,"count":29,"share":30},"PSMA",49,11,{"name":32,"count":33,"share":30},"PDCD1",48,{"name":35,"count":36,"share":37},"AR",37,8,{"name":39,"count":40,"share":41},"VEGFR2",26,6,{"name":43,"count":44,"share":45},"TUBB",23,5,{"name":47,"count":48,"share":45},"VEGFR4",22,{"name":50,"count":51,"share":52},"MET",18,4,{"name":54,"count":55,"share":52},"RET",17,{"name":57,"count":58,"share":52},"CD274",16,[60,64,68,72,75,77,79,82],{"name":61,"count":62,"share":63},"Small molecules",279,63,{"name":65,"count":66,"share":67},"Monoclonal antibodies",150,34,{"name":69,"count":70,"share":71},"Antibody-drug conjugates",86,19,{"name":73,"count":21,"share":74},"Radiopharmaceuticals",15,{"name":76,"count":58,"share":52},"Bispecific antibodies",{"name":78,"count":58,"share":52},"Microbial and phage therapeutics",{"name":80,"count":26,"share":81},"Vaccines",3,{"name":83,"count":84,"share":81},"Peptides",12,[86,90,94,97,100,104,106,109,111,113],{"name":87,"count":88,"share":89},"prostate cancer (PCa)",108,24,{"name":91,"count":92,"share":93},"metastatic castration-resistant prostate cancer (mCRPC)",89,20,{"name":95,"count":96,"share":58},"transitional cell carcinoma (TCC)",73,{"name":98,"count":99,"share":30},"clear cell renal cell carcinoma (ccRCC)",47,{"name":101,"count":102,"share":103},"bladder cancer",42,9,{"name":105,"count":48,"share":45},"renal cell carcinoma (RCC)",{"name":107,"count":108,"share":45},"metastatic renal cell carcinoma (mRCC)",21,{"name":110,"count":93,"share":52},"muscle-invasive bladder carcinoma (MIBC)",{"name":112,"count":55,"share":52},"muscle-invasive bladder cancer (MIBC)",{"name":114,"count":74,"share":81},"urothelial carcinoma (UC)",[116,119,122,126,128,131,133,135,137,139],{"name":117,"count":118,"share":26},"Astellas Pharma",57,{"name":120,"count":121,"share":37},"Merck",35,{"name":123,"count":124,"share":125},"Novartis",32,7,{"name":127,"count":17,"share":41},"Bristol Myers Squibb",{"name":129,"count":130,"share":41},"Bayer",25,{"name":132,"count":44,"share":45},"Pfizer",{"name":134,"count":71,"share":52},"Johnson & Johnson",{"name":136,"count":55,"share":52},"AstraZeneca",{"name":138,"count":55,"share":52},"Exelixis",{"name":140,"count":74,"share":81},"Sanofi",[142,150,156,163,169,175,183,190,198,204,210,216],{"title":143,"drug":144,"company":117,"phase":147,"disease":112,"finding":148,"url":149},"Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible.",{"name":145,"slug":146},"enfortumab vedotin","enfortumab-vedotin","Phase 3","Among pts evaluated for DFS (n = 135 in EV + pembro arm; n = 129 in control arm), median DFS was not reached vs 23.6 mo (HR 0.37; 95% CI 0.23–0.59).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.638",{"title":151,"drug":152,"company":120,"phase":147,"disease":98,"finding":154,"url":155},"Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.",{"name":153,"slug":153},"belzutifan","Median (range) DOR was 23.0 mo (2.0–44.3+) with bel + lenva vs 12.3 mo (1.8+–35.9+) with cabo at IA2.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.lba417",{"title":157,"drug":158,"company":160,"phase":147,"disease":110,"finding":161,"url":162},"Gemcitabine intravesical system (Gem-iDRS) in combination with cetrelimab (CET) versus chemoradiotherapy (CRT) in muscle-invasive bladder cancer (MIBC): SunRISe-2 final results.",{"name":159,"slug":159},"gemcitabine",null,"Gem-iDRS + CET did not show superior BI-EFS over CRT (HR, 1.71 [95% CI, 1.16-2.53]); 24-mo rates were 58.5% vs 66.5%, respectively.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.635",{"title":164,"drug":165,"company":160,"phase":147,"disease":87,"finding":167,"url":168},"Androgen deprivation therapy and radiotherapy with or without cabazitaxel in very-high risk localized prostate cancer: First results of the PEACE-2 randomized phase III trial.",{"name":166,"slug":166},"cabazitaxel","There was no improvement of cPFS with cabazitaxel (HR: 1.11 [0.87-1.41]; 6-year cPFS rates: 67.2% vs 71.4%).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.lba307",{"title":170,"drug":171,"company":129,"phase":147,"disease":87,"finding":173,"url":174},"Efficacy and safety of darolutamide and ADT in patient subgroups by baseline comorbidities and concomitant medications: ARANOTE post hoc analyses.",{"name":172,"slug":172},"darolutamide","An rPFS benefit for DARO vs PBO was seen across all comorbid (≤4, HR 0.46, 95% CI 0.32–0.65; >4, HR 0.58, 95% CI 0.36–0.93) and conmed (≤4, HR 0.48, 95% CI 0.32–0.72; >4, HR 0.61, 95% CI 0.38–0.97) subgroups.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.178",{"title":176,"drug":177,"company":123,"phase":147,"disease":87,"finding":181,"url":182},"Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive mHSPC.",{"name":178,"slug":179,"named_as":180},"lutetium lu 177 vipivotide tetraxetan","lutetium-lu-177-vipivotide-tetraxetan","Lu-PSMA","Overall incidences of grade ≥3 AEs and serious AEs were 50.7% and 26.6%, respectively, in the 177 Lu-PSMA-617 arm and 43.0% and 22.8% in the control arm.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.18",{"title":184,"drug":185,"company":187,"phase":147,"disease":105,"finding":188,"url":189},"Efficacy and safety of avelumab + axitinib vs sunitinib in patients (pts) with very favorable-risk advanced renal cell carcinoma (aRCC): Subgroup analysis from the JAVELIN Renal 101 trial.",{"name":186,"slug":186},"avelumab","Merck KGaA","In the avelumab + axitinib vs sunitinib arms, respectively, treatment-related adverse events of any grade occurred in 100% vs 97.2% pts, including grade ≥3 events in 73.3% vs 61.1%, and led to permanent discontinuation of all study drugs in 0% vs 16.7%.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.560",{"title":191,"drug":192,"company":160,"phase":195,"disease":101,"finding":196,"url":197},"Clinical outcomes of neoadjuvant intravesical mitomycin-C therapy administered immediately prior to TURBT in NMIBC: Over three years of follow-up data from a randomized phase II trial.",{"name":193,"slug":194},"mitomycin c","mitomycin-c","Phase 2","Two doses of INAIC with MMC significantly improved 3- and 5-year PFS rates compared to controls (100% vs. 92.1% and 85.8%; HR 0.078, P = 0.014) and 3- and 5-year CFS rates (100% vs. 97.4% and 91.1%; HR 0.078, P = 0.014) using Firth’s penalized likelihood method.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.771",{"title":199,"drug":200,"company":132,"phase":195,"disease":87,"finding":202,"url":203},"A randomized phase 2 study of enhanced AR blockade with enzalutamide in high-risk patients with biochemical relapse undergoing salvage radiation: Final results from RTOG 3506 (STEEL).",{"name":201,"slug":201},"enzalutamide","The SRT+eARB arm had better PFS when compared to the SRT+sADT arm (HR=0.62, 80% CI: 0.42-0.91, one-sided p=0.052).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.156",{"title":205,"drug":206,"company":160,"phase":195,"disease":98,"finding":208,"url":209},"CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab\u002Fnivolumab for metastatic kidney cancer.",{"name":207,"slug":207},"nivolumab","In per protocol analysis of pts who received 4 cycles of I\u002FN +\u002F- SBRT, 12-month PFS was 46% vs 56%, ORR was 50% vs 44%, and 18-month OS was 74% vs 79%, for I\u002FN+SBRT (n = 24) vs I\u002FN alone (n = 16).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.416",{"title":211,"drug":212,"company":160,"phase":195,"disease":87,"finding":214,"url":215},"SAVE: A multicenter randomized phase 2 trial of salvage radiotherapy (SRT) with androgen-deprivation therapy (ADT) versus apalutamide (Apa) for biochemical progression after radical prostatectomy (RP).",{"name":213,"slug":213},"apalutamide","PSA response rates were similar at 3 (82% with Apa vs 75% with ADT, p = 0.3), 6 (84% vs 73%, p = 0.12) and 9 (76% vs 74%, p = 0.9) months.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.364",{"title":217,"drug":218,"company":160,"phase":195,"disease":98,"finding":220,"url":221},"Metastasis-directed therapy with or without pembrolizumab for oligometastatic clear cell renal cell carcinoma: Pooled analysis of two prospective single-arm phase II trials.",{"name":219,"slug":219},"pembrolizumab","Adjusted for prognostic factors, median PFS was 28 months after MDT+ICI and 17 months after MDT (HR, 0.57; 95% CI: 0.31 to 0.998; P = 0.049).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.7_suppl.498",{"summary":223,"bullets":225},[224],"Small molecules were the most frequent modality (63% of drug-linked abstracts). PVRL4 was the most frequent target (13%). Prostate cancer (PCa) was the most frequent disease (24%).",[226,227,228,229,230],"Astellas Pharma had the largest company share (13% of drug-linked abstracts).","Antibody-drug conjugates accounted for 19% of drug-linked abstracts.","Bispecific antibodies accounted for 4% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (34%).","PSMA was the next most frequent target (11%).",[],[233,234],{"name":69,"count":70,"share":71,"previous_count":160,"previous_share":160,"direction":160},{"name":76,"count":58,"share":52,"previous_count":160,"previous_share":160,"direction":160},1793970603095]